UK's GSK to acquire U.S. drugmaker Nuvalent for $10.6 billion as pharma giants race to expand pipelines
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
UK's GSK to acquire U.S. drugmaker Nuvalent for $10.6 billion as pharma giants race to expand pipelines basliginda one cikan gelisme: The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.